24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Kåre Schultz
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
11:14
“The revolutionary AI social network is largely humans operating fleets of bots”
10:27
“Israeli tech post-October 7th could not be in a better position”
10:26
“It may feel uneasy, but letting software act independently isn’t optional, it’s necessary for survival today”
10:24
“One of the most undervalued opportunities is next-gen HR and talent intelligence”
More stories
Buzz
Most popular
Daily
Weekly
1
Chinese fund: “The Chinese government has imposed a ban on any new investment in Israel”
2
Israeli defense firms target Asia as Singapore Airshow opens amid regional arms race
3
Medtronic to acquire Israeli AI cardiology firm CathWorks for $585 million, deal could reach $1 billion
4
After $400M cyber exit, ex-IntSights CEO raises $11M to build AI app for personalized sports highlights
5
“SaaS is dying as a business category”
More news
Kåre Schultz
9 stories about Kåre Schultz
Teva Announces Restructuring, Ousts Second in Command
27.11.17
|
Golan Hazani
The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately
Israeli Parliamentarians to Push Against Teva Layoffs in the Country
26.11.17
|
Dror Reich and Maayan Manela
Shelly Yachimovich, a member of the Israeli parliament representing the Israeli Labor Party, said she intends to call an emergency hearing of the Israeli parliament’s state control committee on the issue. The planned layoffs are a result of the company’s management failures, she added
Troubled Drugmaker Teva to Axe over 4,000 Jobs
23.11.17
|
Golan Hazani
Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden
Generic Dependence Threatens Teva’s Ability to Haul Debt Load
05.11.17
|
Dror Reich and Lilach Baumer
Teva’s stock price dropped 18.7% last week after the company lowered its annual forecasts. On Friday, S&P changed the company’s outlook to negative
With New CEO in Seat, Teva Lowers Outlook
02.11.17
|
Lilach Baumer and Dror Reich
Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
New CEO to Take Helm at Troubled Teva Wednesday
31.10.17
|
Lilach Baumer
The generic drugmaker shed 67% of its market price over the last 12 months
New Teva CEO Kåre Schultz to Relocate to Israel
17.10.17
|
Golan Hazani
Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month
The Ten Challenges Facing Teva's New CEO
12.09.17
|
Sophie Shulman
Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board
Teva Appoints Lundbeck's Schultz as CEO
11.09.17
|
Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
Previous Articles